CRIS (Curis, Inc.) Stock Financials & Earnings | Market Cap Arena

CRIS (Curis, Inc.) Stock Financials & Earnings | Market Cap Arena

CRISCuris, Inc.

Mkt Cap$15M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$12M

Net Income (TTM)-$37M

EPS (TTM)-$3.67

Free Cash Flow (TTM)-$30M

Gross Margin99.5%

Op. Margin-294.6%

Net Margin-313.8%

FCF Margin-258.3%

P/S Ratio (TTM)1.3x

P/E Ratio (TTM)—

YoY Rev Growth+13.6%

Employees—

Earnings Reports

Next: Q4 2025 · Mar 17

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q4 22	$3M	$3M	-$10M
Q1 23	$2M	$2M	-$12M
Q2 23	$2M	$2M	-$12M
Q3 23	$3M	$3M	-$12M
Q4 23	$3M	$3M	-$12M
Q1 24	$2M	$2M	-$12M
Q2 24	$3M	$3M	-$13M
Q3 24	$3M	$3M	-$11M
Q4 24	$3M	$3M	-$9M
Q1 25	$2M	$2M	-$10M
Q2 25	$3M	$3M	-$8M
Q3 25	$3M	$3M	-$7M

Valuation

Quarter	P/S	P/E
Q4 22	1.5x	—
Q1 23	1.4x	—
Q2 23	1.5x	—
Q3 23	1.5x	—
Q4 23	1.5x	—
Q1 24	1.5x	—
Q2 24	1.5x	—
Q3 24	1.5x	—
Q4 24	1.4x	—
Q1 25	1.3x	—
Q2 25	1.3x	—
Q3 25	1.3x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q4 22	-$12M	-$12M
Q1 23	-$12M	-$12M
Q2 23	-$8M	-$8M
Q3 23	-$8M	-$8M
Q4 23	-$10M	-$10M
Q1 24	-$13M	-$13M
Q2 24	-$11M	-$11M
Q3 24	-$6M	-$6M
Q4 24	-$9M	-$9M
Q1 25	-$7M	-$7M
Q2 25	-$8M	-$8M
Q3 25	-$6M	-$6M

Capital Expenditures

CapEx

Quarter	CapEx
Q4 22	$0
Q1 23	$0
Q2 23	$0
Q3 23	$0
Q4 23	$0
Q1 24	$0
Q2 24	$0
Q3 24	$0
Q4 24	$0
Q1 25	$0
Q2 25	$0
Q3 25	$0

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q4 22	-7.9%	-16.5%
Q1 23	+11.7%	-19.0%
Q2 23	-8.2%	-17.9%
Q3 23	+0.3%	-1.5%
Q4 23	-6.6%	+13.6%
Q1 24	-9.2%	+4.5%
Q2 24	+15.9%	+5.0%
Q3 24	+3.5%	-11.2%
Q4 24	+24.1%	-17.2%
Q1 25	+14.1%	-13.9%
Q2 25	+8.0%	-26.9%
Q3 25	+8.4%	-25.2%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q4 22	$2M	60.4%
Q1 23	$1M	60.7%
Q2 23	$0	0.0%
Q3 23	$2M	57.6%
Q4 23	$2M	57.4%
Q1 24	$0	0.0%
Q2 24	$2M	66.9%
Q3 24	$1M	47.2%
Q4 24	$1M	38.3%
Q1 25	$1M	48.9%
Q2 25	$1M	41.3%
Q3 25	$924K	29.1%

OpEx Breakdown

Quarter	R&D	G&A
Q4 22	$9M	$4M
Q1 23	$9M	$5M
Q2 23	$10M	$4M
Q3 23	$10M	$5M
Q4 23	$10M	$5M
Q1 24	$10M	$5M
Q2 24	$10M	$5M
Q3 24	$10M	$4M
Q4 24	$9M	$3M
Q1 25	$9M	$4M
Q2 25	$7M	$4M
Q3 25	$6M	$4M

Revenue Segments

Quarter	Contra Revenue	Gross Royalty Revenue	Reportable Segment
Q4 22	-$14K	$3M	—
Q1 23	—	$2M	—
Q2 23	—	$2M	—
Q3 23	—	$3M	—
Q4 23	—	$3M	—
Q1 25	—	—	$2M
Q2 25	—	—	$3M
Q3 25	—	—	$3M

War Chest

Quarter	Cash	Short-term Investments	Total
Q4 22	$20M	$66M	$86M
Q1 23	$32M	$40M	$72M
Q2 23	$20M	$44M	$63M
Q3 23	$24M	$44M	$68M
Q4 23	$27M	$30M	$56M
Q1 24	$30M	$11M	$41M
Q2 24	$10M	$18M	$28M
Q3 24	$21M	$0	$21M
Q4 24	$20M	$0	$20M
Q1 25	$20M	$0	$20M
Q2 25	$10M	$0	$10M
Q3 25	$9M	$0	$9M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q4 22	5M	+2.8%
Q1 23	5M	+0.2%
Q2 23	5M	+0.1%
Q3 23	6M	+18.3%
Q4 23	6M	+0.9%
Q1 24	6M	+0.2%
Q2 24	6M	+0.6%
Q3 24	6M	+2.1%
Q4 24	8M	+29.1%
Q1 25	8M	+10.7%
Q2 25	13M	+48.7%
Q3 25	16M	+24.2%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 13	$455K	33
FY 14	$281K	35
FY 15	$179K	44
FY 16	$130K	58
FY 17	$180K	55
FY 18	$336K	31
FY 19	$357K	28
FY 20	$387K	28
FY 21	$177K	60
FY 22	$199K	51
FY 23	$205K	49
FY 24	$321K	34